KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Accumulated Expenses (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Other Accumulated Expenses for 13 consecutive years, with $966000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 35.29% to $966000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $966000.0 through Dec 2025, up 35.29% year-over-year, with the annual reading at $966000.0 for FY2025, 35.29% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $966000.0 at Xenon Pharmaceuticals, up from $935000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $1.1 million in Q2 2024, with the low at $26000.0 in Q3 2021.
  • Average Other Accumulated Expenses over 5 years is $418842.1, with a median of $282000.0 recorded in 2022.
  • Peak annual rise in Other Accumulated Expenses hit 1106.59% in 2024, while the deepest fall reached 86.13% in 2024.
  • Over 5 years, Other Accumulated Expenses stood at $118000.0 in 2021, then surged by 188.98% to $341000.0 in 2022, then plummeted by 68.62% to $107000.0 in 2023, then skyrocketed by 567.29% to $714000.0 in 2024, then skyrocketed by 35.29% to $966000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $966000.0, $935000.0, and $439000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.